Literature DB >> 9179512

Cost-effectiveness of treatment for drug-abusing pregnant women.

D S Svikis1, A S Golden, G R Huggins, R W Pickens, M E McCaul, M L Velez, C T Rosendale, R K Brooner, P M Gazaway, M L Stitzer, C E Ball.   

Abstract

Neonatal intensive care unit (NICU) and drug treatment costs were compared in two groups of pregnant drug abusing women: 100 admissions to a multidisciplinary treatment program and active in care at the time of delivery and 46 controls not entering drug treatment. Clinical measures included urine toxicology at delivery, infant birthweight. Apgar scores and need for and duration of NICU services. Cost measures included drug treatment and NICU costs. Treatment patients showed better clinical outcome at delivery, with less drug use and higher infant estimated gestational age, birthweight and Apgar scores. Infants of treatment patients were also less likely to require NICU services and, for those that did, had a shorter stay. When total cost was examined (including drug treatment), mean net savings for treatment subjects was $4644 per mother/infant pair. The study demonstrates the cost-effectiveness of treatment for pregnant drug abusing women, with savings in NICU costs exceeding costs of drug treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9179512     DOI: 10.1016/s0376-8716(97)01352-5

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  26 in total

1.  Physician response to prenatal substance exposure.

Authors:  G L Zellman; R M Bell; C Archie; H DuPlessis; J Hoube; A Miu
Journal:  Matern Child Health J       Date:  1999-03

2.  Assessment of benefits of a universal screen for maternal alcohol use during pregnancy.

Authors:  Anne E Gifford; Kathleen J Farkas; Leila W Jackson; Christopher D Molteno; Joseph L Jacobson; Sandra W Jacobson; Cynthia F Bearer
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-10

Review 3.  Substance abuse treatment entry, retention, and outcome in women: a review of the literature.

Authors:  Shelly F Greenfield; Audrey J Brooks; Susan M Gordon; Carla A Green; Frankie Kropp; R Kathryn McHugh; Melissa Lincoln; Denise Hien; Gloria M Miele
Journal:  Drug Alcohol Depend       Date:  2006-06-08       Impact factor: 4.492

4.  Substance abuse treatment for women: changes in the settings where women received treatment and types of services provided, 1987-1998.

Authors:  Christine E Grella; Lisa Greenwell
Journal:  J Behav Health Serv Res       Date:  2004 Oct-Dec       Impact factor: 1.505

5.  Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment.

Authors:  Brandi Jancaitis; Sydney Kelpin; Saba Masho; James May; Nancy A Haug; Dace Svikis
Journal:  Women Health       Date:  2019-05-08

6.  Reciprocal obligations: managing policy responses to prenatal substance exposure.

Authors:  Peter D Jacobson; Gail L Zellman; C Christine Fair
Journal:  Milbank Q       Date:  2003       Impact factor: 4.911

7.  Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment.

Authors:  Marcus A Bachhuber; Pooja K Mehta; Laura J Faherty; Brendan Saloner
Journal:  Med Care       Date:  2017-12       Impact factor: 2.983

8.  A therapeutic workplace for the long-term treatment of drug addiction and unemployment: eight-year outcomes of a social business intervention.

Authors:  Will M Aklin; Conrad J Wong; Jacqueline Hampton; Dace S Svikis; Maxine L Stitzer; George E Bigelow; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2014-07-12

9.  Cost-effectiveness of individual versus group female-specific cognitive behavioral therapy for alcohol use disorder.

Authors:  Todd A Olmstead; Fiona S Graff; Alyssa Ames-Sikora; Barbara S McCrady; Ayorkor Gaba; Elizabeth E Epstein
Journal:  J Subst Abuse Treat       Date:  2019-02-07

10.  Should pregnant women with substance use disorders be managed differently?

Authors:  Verena Metz; Birgit Köchl; Gabriele Fischer
Journal:  Neuropsychiatry (London)       Date:  2012-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.